Do you find our website to be helpful?
Yes   No

Michael Tolentino, MD

Ophthalmologist located in Delray Beach, FL

About Dr. Tolentino

Doctor Michael Tolentino is a Board-Certified Ophthalmologist fellowship trained in the treatment of all medical and surgical retinal disease and laser surgery. This includes diabetic retinopathy, macular degeneration, macular puckers, retinal tears, complex retinal detachments, and retinal degenerations such as retinitis pigmentosa.

While attending Brown University, Dr. Michael Tolentino helped develop a cataract imaging system at the National Eye Institute (NEI). In medical school at UMASS he worked at the Berman-Gund Lab at Harvard Medical School studying Macular Degeneration and Retinitis Pigmentosa. This background led him to the laboratory of Dr. Judah Folkman at Harvard Medical School where he demonstrated the importance of Vascular Endothelial Growth Factor(VEGF) in diabetic retinopathy and macular degeneration and was the first to test and purify Avastin as an eye injection. This research was the basis for the drugs Lucentis, Eylea, Avastin and Macugen. While continuing to develop eye injections, he completed his Ophthalmology Residency at the Harvard Medical School.

He then moved to the University of Pennsylvania for his vitreo-retinal surgical fellowship. He had a joint appointment as a member of the Cellular and Molecular Biology Faculty at UPENN and ran a NEI sponsored laboratory where he invented a VEGF gene silencing molecule called Bevasiranib. He also researched the use of gene and stem cell therapy for use in retinal disease. In parallel he refined his surgical skills as one of the main ophthalmic trauma surgeons in Philadelphia and the main Veterans Administration retina surgeon for the northern mid-Atlantic region. He eventually became the director of the vitreo-retinal surgical fellowship at UPENN.

After helping develop anti-VEGF medications in the laboratory, he moved to central Florida to refocus his research on the clinical development and founded one of the largest retinal clinical research centers in the world. He went on to be principal investigator in over 120 retinal clinical trials helping seven retinal therapies get FDA approval. To pursue his passion for teaching, he joined the faculty of the University of Central Florida Medical School as a Clinical Associate Professor.

Dr. Tolentino continues to develop new concepts in retinal care and is a pioneer in his field. His dedication to ophthalmology ensures that each patient receives the best care and a professional experience.

Read more
,  Office of Michael Tolentino, MD

Doctor Michael Tolentino is a Board-Certified Ophthalmologist fellowship trained in the treatment of all medical and surgical retinal disease and laser surgery. This includes diabetic retinopathy, macular degeneration, macular puckers, retinal tears, complex retinal detachments, and retinal degenerations such as retinitis pigmentosa.

While attending Brown University, Dr. Michael Tolentino helped develop a cataract imaging system at the National Eye Institute (NEI). In medical school at UMASS he worked at the Berman-Gund Lab at Harvard Medical School studying Macular Degeneration and Retinitis Pigmentosa. This background led him to the laboratory of Dr. Judah Folkman at Harvard Medical School where he demonstrated the importance of Vascular Endothelial Growth Factor(VEGF) in diabetic retinopathy and macular degeneration and was the first to test and purify Avastin as an eye injection. This research was the basis for the drugs Lucentis, Eylea, Avastin and Macugen. While continuing to develop eye injections, he completed his Ophthalmology Residency at the Harvard Medical School.

He then moved to the University of Pennsylvania for his vitreo-retinal surgical fellowship. He had a joint appointment as a member of the Cellular and Molecular Biology Faculty at UPENN and ran a NEI sponsored laboratory where he invented a VEGF gene silencing molecule called Bevasiranib. He also researched the use of gene and stem cell therapy for use in retinal disease. In parallel he refined his surgical skills as one of the main ophthalmic trauma surgeons in Philadelphia and the main Veterans Administration retina surgeon for the northern mid-Atlantic region. He eventually became the director of the vitreo-retinal surgical fellowship at UPENN.

After helping develop anti-VEGF medications in the laboratory, he moved to central Florida to refocus his research on the clinical development and founded one of the largest retinal clinical research centers in the world. He went on to be principal investigator in over 120 retinal clinical trials helping seven retinal therapies get FDA approval. To pursue his passion for teaching, he joined the faculty of the University of Central Florida Medical School as a Clinical Associate Professor.

Dr. Tolentino continues to develop new concepts in retinal care and is a pioneer in his field. His dedication to ophthalmology ensures that each patient receives the best care and a professional experience.


Read less

Accepted Insurance Providers

Please note that we accept MEDICAL insurance (not VISION insurance). This is not a comprehensive list of accepted insurance providers. Check out our Patient Information Page for more information or contact our office directly for any coverage-related questions. Thank you. *Patients should always contact the office directly to see if we are still active with their insurance carrier.

Aetna
Blue Cross Blue Shield
Cigna
Humana
Medicare
Self Pay
United Healthcare